A practical UK guide to NHS obesity-medication pathways: who prescribes Mounjaro, Wegovy, Saxenda and Orlistat, primary care vs specialist services, NICE vs NHS commissioning, phased access, local variation, refusals and private alternatives.
Updated 8 August 2026England pathway focusNICE + NHS EnglandPrimary care + specialist
Start here: the NHS does not have one single weight-loss medication pathway
The NHS can prescribe obesity medicines, but the route depends on the medicine, the NICE recommendation, NHS commissioning rules, local ICB arrangements and whether prescribing sits in primary care or a specialist weight-management service.
That is why one person can be told “your GP cannot prescribe this” while another is receiving the same medicine through a specialist clinic. Both statements can be correct in context.
The first thing to understand is that NICE approval is not identical to instant nationwide prescribing through every GP surgery.
The NHS medication map
Mounjaro
Tirzepatide. Strongest current obesity efficacy of the mainstream licensed options. NHS primary-care access is being phased, while specialist services may prescribe under the full NICE criteria.
NICE says yes. Does that mean the NHS must prescribe it immediately?
No. NICE technology appraisals determine whether a medicine is recommended for NHS use in defined groups, but NHS England and local commissioners still have to implement the treatment pathway.
Tirzepatide is the clearest current example. NICE recommends it for eligible adults, but NHS England has introduced phased primary-care implementation because the eligible population is extremely large.
Useful distinction:
Clinical eligibility answers “does NICE say this treatment may be appropriate?” Service access answers “is there currently a commissioned route to prescribe it to me here?”
Primary care vs specialist prescribing
Route
What it means
Typical examples
Primary care
Your GP practice or primary-care network can initiate/manage treatment if the local NHS pathway allows it.
Orlistat; phased tirzepatide access in eligible priority cohorts.
Specialist weight management
Multidisciplinary service with obesity expertise, often hospital/community based.
Wegovy; full NICE-eligible tirzepatide population where commissioned; complex obesity cases.
Shared care / handover
Specialist may start treatment and primary care may later continue monitoring where local arrangements allow.
Varies by medicine and ICB.
Mounjaro (tirzepatide): the NHS pathway
NICE TA1026 recommends tirzepatide for managing overweight and obesity in eligible adults when BMI and weight-related comorbidities meet the stated criteria.
NHS England's implementation is split into two broad routes:
Specialist weight-management services: may prescribe to the wider NICE-eligible population where clinically appropriate and commissioned.
Primary care: access is being phased, initially prioritising people at highest clinical need using BMI plus multiple obesity-related conditions.
This is why “my GP says they can't prescribe Mounjaro yet” can be true even where NICE says you meet the treatment criteria.
Primary-care Mounjaro prescribing also requires behavioural/wraparound support as part of NHS England's implementation model.
Wegovy (semaglutide): the NHS pathway
Wegovy is a licensed obesity treatment and has an established place within NHS specialist weight-management services for eligible adults.
In practice, access is usually more specialist-led than ordinary GP prescribing. Local ICB pathways may define which services can assess and initiate treatment.
Some areas may use specialist services for initiation and then arrange follow-up differently. The exact route therefore needs to be checked locally.
Saxenda (liraglutide): where does it fit now?
Saxenda was one of the earlier GLP-1 weight-management medicines. Its once-daily injection and more modest average weight loss mean it is less prominent now than Wegovy or Mounjaro.
It may still be encountered in specialist services, particularly where newer treatments are unsuitable, unavailable or not tolerated. Local formularies and commissioning matter.
Orlistat: the most established primary-care option
Orlistat is an oral medicine that reduces absorption of dietary fat. It does not act on GLP-1 or appetite hormones.
Unlike newer injectable medicines, orlistat has long been available through ordinary primary-care prescribing when clinically appropriate. It remains relevant where injections are unsuitable, unaffordable privately or inaccessible through NHS specialist pathways.
Why is Mounjaro being rolled out slowly?
The number of adults who potentially meet NICE criteria is very large. NHS England therefore introduced a prioritised implementation approach rather than opening primary-care prescribing to everyone at once.
Initial cohorts focus on people with the greatest combination of obesity severity and related health conditions. The rollout is designed to expand over time as capacity, prescribing systems and behavioural-support services develop.
That means the answer to “when will I qualify through my GP?” can change over time without NICE changing the medicine recommendation itself.
What is wraparound support?
NHS obesity medicines are not intended to be issued as isolated prescriptions. Wraparound support typically includes nutrition, physical activity and behavioural support alongside clinical monitoring.
For primary-care tirzepatide, NHS England explicitly requires behavioural support as part of the commissioned treatment offer.
Why does access vary by ICB?
ICBs commission local services. They decide how national guidance is turned into practical local pathways, including which providers initiate treatment, how referrals work and how quickly new services are rolled out.
One ICB may have a mature specialist obesity service. Another may still be building capacity. This creates real local variation even when both are working within national NICE and NHS England guidance.
Who can refer or prescribe?
Depending on the route, referrals may come from GPs, hospital specialists or other healthcare professionals. Some digital/community services allow self-referral, but prescription medicines generally require clinician assessment.
Prescribing responsibility may sit with a GP, specialist obesity clinician or another qualified prescriber working within the NHS service.
What checks might happen before medication?
Clinical assessment may include weight/BMI, blood pressure, diabetes status, liver and kidney function, medication history, pregnancy status where relevant, pancreatitis/gallbladder history, gastrointestinal symptoms and eating-disorder/mental-health considerations.
Not every person needs exactly the same blood tests. The prescriber decides based on the medicine and your health.
What if you are told you cannot have the medicine?
Ask why. There are several completely different reasons:
You do not meet the clinical criteria.
You meet NICE criteria but are not yet in the local phased cohort.
Your ICB does not yet have a pathway active in your setting.
You need referral to specialist weight management rather than GP prescribing.
A medical contraindication or safety issue makes the medicine unsuitable.
Another treatment is recommended first.
The next step depends on which of those applies.
NHS vs private medication
NHS
Private
Cost
NHS-funded; normal prescription-charge rules may apply
Monthly medicine + provider fees
Eligibility
NICE + NHS commissioning / rollout
Licensed indication + clinician assessment
Speed
Can involve waiting / phased access
Usually faster
Choice
Pathway-dependent
Usually broader
Support
Service-based support
Quality varies substantially by provider
If you go private while waiting for NHS access, make sure your GP knows what you are taking and do not assume the NHS will automatically take over prescribing later.
NHS Medication Finder
This is a pathway guide, not a clinical eligibility decision. It helps you work out what NHS conversation is most sensible to have next.
Questions to ask your GP or specialist
Do I meet NICE criteria for any obesity medicines?
Is tirzepatide available through primary care in my current ICB cohort?
If not, can I be referred to specialist weight management?
Can the specialist service prescribe to the full NICE criteria?
Is Wegovy available locally?
Would orlistat be reasonable while I wait?
What behavioural support is included?
What baseline checks do I need?
Who monitors side effects?
What happens if I lose access after starting?
If I go private, will the NHS later take over prescribing?
What is the waiting time for the relevant service?
Shift Says
If you were our brother...
We would not ask one question — “Can I have Mounjaro?” — and stop there.
We'd ask: Which NHS obesity medicines do I qualify for? Which route is active locally? Can primary care prescribe, or do I need specialist referral? What can I do while I wait?
The medicine matters. The pathway matters almost as much.
Printable NHS medication checklist
I know which medicines are clinically relevant to me.
I know whether the route is primary care or specialist.
I know whether local phased access applies.
I know what wraparound support is included.
I know what baseline checks are needed.
I know why I have been refused, if applicable.
I know what alternative NHS route exists.
I understand the difference between NHS and private prescribing.
NHS medication FAQs
Can my GP prescribe Mounjaro for weight loss?
Potentially, but NHS primary-care access is being phased and depends on national priority cohorts plus local implementation.
Can a specialist service prescribe Mounjaro if my GP cannot?
Specialist weight-management services can operate under the wider NICE-eligible population where commissioned and clinically appropriate.
Can I get Wegovy on the NHS?
Yes for eligible adults, usually through specialist weight-management pathways.
Is Saxenda still available on the NHS?
It may still be used in some specialist pathways, though newer medicines are now more prominent.
Can my GP prescribe Orlistat?
Yes, if clinically appropriate.
Does NICE approval guarantee access?
No. Commissioning, rollout and service capacity still matter.
Why does my friend get Mounjaro through the NHS and I cannot?
They may be in a different clinical priority cohort, ICB or specialist service.
Can I self-refer for weight-loss injections?
Prescription medicines require clinician assessment; some related weight-management services may allow self-referral.
Do I need diabetes to get Mounjaro for obesity?
No. The obesity indication is separate from the diabetes indication, though comorbidities affect NHS priority.
Will I have to pay prescription charges?
Normal England prescription-charge rules apply unless you are exempt.
Can I go private then switch to NHS?
Possibly, but NHS takeover is not automatic and depends on eligibility and local pathways.
What happens if I do not tolerate one medicine?
A clinician may consider dose adjustment, stopping or an alternative treatment depending on the medicine and your health.
Can I get medication if I am waiting for surgery?
Potentially, under specialist review; medication can sometimes be used before or after bariatric surgery.
Is wraparound support compulsory?
For some NHS medication pathways, including primary-care tirzepatide implementation, behavioural support is part of the commissioned model.
Do I need blood tests before treatment?
Often some baseline checks are appropriate, but exactly which tests you need depends on your health and the medicine.
Can I appeal a refusal?
You can ask for the reason and pathway criteria, seek re-referral where appropriate and use local NHS complaints/patient-advice routes if you think rules were applied incorrectly.
Is Orlistat weaker than injections?
Average weight loss is generally lower than with newer incretin medicines, but it is an established non-injectable option.
Can the NHS prescribe Ozempic for weight loss?
Ozempic is primarily a type 2 diabetes medicine; NHS obesity prescribing should follow the appropriate licensed/NICE weight-management products and pathways.
What if my BMI is under 30?
Most NHS obesity-medicine pathways will not apply unless a specific indication or lower ethnicity-adjusted threshold is relevant.
What is the best first question to ask?
Ask which NHS obesity-medication pathways are active locally and which, if any, you meet.
Sources & further reading
Medication commissioning changes quickly. We prioritise NICE and NHS England sources and date-stamp the guide.
Use the NHS route first if it works for you. If you later want structured support from Shift, tell us how we can reach out when the programme is ready.
